FOXO4-DRI identity testing uses two independent measurements read together. A deconvoluted mass from ESI-MS must match the theoretical value within a stated tolerance. A chromatographic trace must show that mass belongs to the main peak. Neither one can see the retro-inverso design, so chirality needs a separate chiral or spectroscopic method.
- Identity and purity are separate claims: a purity percentage describes how much of one component is present, never what that component is.
- FOXO4-DRI is a retro-inverso D-amino acid construct, and neither mass spectrometry nor achiral reversed-phase chromatography can see the configuration that defines it.
- Chirality is confirmed by chiral amino acid analysis after hydrolysis, by circular dichroism against an L reference, or by resistance to protease cleavage.
- An observed mass without an instrument and a tolerance is a number rather than a measurement.
- Gross vial weight for a polybasic peptide includes trifluoroacetate counterion and water, so net peptide content is needed before any concentration is calculated.
- No USP or Ph. Eur. monograph covers this peptide, so no compendial identity test exists and the supplier's method is the only method.
Why do identity and purity answer different questions?
Think of it like a pair of gloves. A left glove and a right glove weigh the same, so a scale cannot tell them apart. Mass spectrometry is that scale: it confirms the weight of FOXO4-DRI, while showing that its building blocks are the mirror-image D form takes a separate chiral test.
A purity figure tells you how much of the material in the vial is the main component. An identity test tells you what that main component is. The two are established by different measurements, and a certificate can carry a very clean number for one while saying nothing useful about the other.
This matters more for FOXO4-DRI than for most research peptides, because the feature that defines the compound is the one that standard analysis is least able to see. The construct described in the primary literature is a retro-inverso peptide: the sequence order is reversed and the residues are D-enantiomers. Reverse the order of an amino acid sequence and you change nothing about its molecular formula. Swap L residues for D and you change nothing about the mass either. A mass spectrum of the intended compound and a mass spectrum of several wrong compounds look the same.
So the question in the title has a longer answer than a single number on a page. What follows is the evidence chain a competent laboratory assembles, and where it stops being able to tell you anything.
- ESI-MS — molecular mass and adduct pattern; blind to chirality
- Top-down MS/MS — partial sequence order; Leu and Ile indistinguishable
- RP-HPLC at 214 nm — area percent among eluting UV absorbers only
- Second orthogonal method — tests for anything hiding under the main peak
- Chiral AAA, CD or protease challenge — the only evidence of D-configuration
- Karl Fischer, ion chromatography, AAA content — what the label weight actually is
What molecule does the documentation have to describe?
FOXO4-DRI, as reported by Baar and colleagues in Cell in 2017, joins a segment derived from FOXO4 to a TAT-derived polybasic import sequence, with the whole construct built as a D-amino acid retro-inverso peptide. The retro-inverso arrangement was chosen because reversing the backbone while inverting residue chirality leaves side-chain topology roughly where it was, and the resulting molecule is not a substrate for mammalian proteases. The published construct sits a little above 5 kDa. The exact theoretical mass depends on the residue count and on how the termini are capped, and the only figure worth calculating from is the sequence printed on the certificate for your own lot.
Two physical consequences follow from the basic residues. First, the material is almost always supplied as a trifluoroacetate salt with a substantial counterion burden, because every arginine and lysine site can carry one. Second, it is hygroscopic and it adsorbs to glass and to some plastics at low concentration. Both facts bear on how the certificate should report content, which is a separate matter from identity and is covered further down.
What does the mass spectrum establish?
Electrospray ionization on a polybasic peptide of this size produces a charge envelope rather than a single ion. Expect a family of species in the 3+ to 6+ region, sometimes higher, and expect the distribution to shift with the mobile phase and the source conditions. Two checks apply before the mass is worth reading. Isotope spacing within a peak should equal 1/z, which is what confirms the charge state you assigned. The deconvoluted neutral mass from separate charge states should agree with itself; if the 4+ and the 5+ deconvolute to different masses, something in the assignment is wrong.
The reported mass then has to arrive with a tolerance and an instrument. A high-resolution TOF or Orbitrap measurement quoted in ppm against a monoisotopic calculation is a real identity claim. A linear-mode MALDI figure at 5 kDa may carry several daltons of uncertainty, which is enough to catch a missing residue and not enough to catch a deamidation. A certificate that prints an observed mass with no tolerance, no instrument, and no indication of whether the value is monoisotopic or average has published a number rather than a measurement.
Sequence-level confirmation is harder here than usual. Bottom-up peptide mapping depends on enzymatic digestion, and the whole point of the all-D backbone is that trypsin and chymotrypsin will not cleave it. Failed digestion is itself weak evidence of D-configuration, but it means the routine mapping workflow described in the compendial peptide-mapping literature is unavailable. Sequence order has to come from top-down fragmentation of the intact species, and coverage on a heavily charged 5 kDa peptide is often partial. Leucine and isoleucine remain isobaric under any of these methods.
Which mass differences should you recognize?
Most synthesis problems announce themselves as a satellite peak at a predictable offset from the target mass. Reading the offsets is a large part of certificate literacy, and it separates a solvent adduct from a covalent defect.
| Offset | Likely cause | Covalent? | Reading |
|---|---|---|---|
| +1.0 | Deamidation of Asn or Gln | Yes | Needs resolution better than MALDI linear mode to see at all |
| +16 | Oxidation, typically Met or Trp | Yes | Often grows with age and light exposure of the lot |
| +22 / +38 | Sodium or potassium adduct | No | Gas-phase artifact; not a purity defect |
| +114 | Trifluoroacetate adduct | No | Expected from TFA mobile phase and TFA salt form |
| +56 / +100 / +242 / +252 | Residual tBu, Boc, trityl or Pbf protecting group | Yes | Incomplete deprotection; a synthesis failure, not handling |
| Minus one residue mass | Deletion during chain assembly | Yes | Closest peak in identity to the target; the hardest to reject by eye |
| Roughly double | Dimer or gas-phase cluster | Depends | Chromatography decides which |
Deletion sequences are the ones to watch. A peptide missing a single glycine differs from the correct compound by 57 Da, behaves almost identically on a C18 column, and is a different molecule. This is why the mass spectrum and the chromatogram have to be read as a pair rather than filed as two separate certificates.
What does chromatography add?
The standard method is reversed-phase HPLC on a C18 stationary phase with an acetonitrile gradient in dilute trifluoroacetic acid, monitored at 214 nm where the amide backbone absorbs. Where the sequence includes aromatic residues, a second trace at 280 nm gives an independent handle on the same peak and a usable route to concentration by absorbance.
What chromatography contributes to identity is not the retention time by itself. Retention time is method-specific and worthless without the column, gradient and flow rate that produced it. The contribution is peak assignment: an LC-MS run ties the target mass to the peak that carries the area percentage, so the purity figure and the identity claim refer to the same substance. Purity reported from one instrument and identity from another, with no run linking them, leaves an assumption in the middle of the record.
Two things make a chromatogram readable. The axes must be labeled and the full run must be shown, including the wash. A trace that ends thirty seconds after the main peak has hidden every late-eluting impurity in the sample. And a second method with different selectivity, usually a shift to near-neutral pH with an ammonium salt buffer or a different phase chemistry, is what tests whether anything is co-eluting under the main peak. Single-method purity is a first estimate.
Why is chirality the hard part?
Consider four molecules built from the same residues: the all-L forward peptide, the all-D forward peptide, the all-L reversed peptide, and the all-D reversed peptide. That last one is FOXO4-DRI. All four share a molecular formula. All four give the same mass on any instrument ever built, because mass spectrometry measures mass and chirality has none.
Achiral reversed-phase chromatography does slightly better. The forward and reversed constitutions are different molecules and can, with luck and a good gradient, resolve. Within an enantiomeric pair there is nothing to resolve: the all-D reversed peptide and the all-L reversed peptide co-elute exactly on a C18 column. So the combination of ESI-MS and RP-HPLC, which is the entire analytical package on most research-peptide certificates, cannot distinguish the compound described in the literature from its mirror image. Partial epimerization at individual residues during synthesis produces diastereomers, which sometimes do separate, and those are the shoulders and front-running humps that a careful chromatogram shows.
Three methods close the gap, none of them routine on a commercial certificate.
- Chiral amino acid analysis. Total acid hydrolysis, then derivatization with Marfey's reagent to make diastereomers of each residue, then RP-HPLC against L and D standards. This reports the D fraction residue by residue. It has caveats: hydrolysis itself racemizes a small percentage, so a control hydrolysate is needed to set the baseline, and tryptophan does not survive the conditions.
- Circular dichroism. Run against the all-L counterpart, a D-peptide gives a near mirror-image spectrum. The sign of the signal is the answer, which makes this a fast qualitative check when a reference is available.
- Protease challenge. Incubate with trypsin and look for cleavage by LC-MS. An all-D backbone is not a substrate; an L or partly L preparation will be cut. This is cheap, orthogonal, and reported far too rarely.
If none of these appears on the documentation, the honest description of what has been confirmed is composition and connectivity, with configuration taken on the manufacturer's word. That is a defensible position for a research material provided it is written down as such rather than glossed over.
Why does a purity percentage prove nothing on its own?
A purity figure is an area percentage at one wavelength on one method. It says that 98 or 99 percent of the UV-absorbing material that eluted during the run sat in one peak. It says nothing about what that peak is, nothing about material that never eluted, and nothing about anything in the vial that does not absorb at 214 nm.
The last point drives the arithmetic. A vial labeled 10 mg is usually 10 mg of gross weight, which includes trifluoroacetate counterion, residual water and residual solvent. For a peptide with this many basic sites the counterion alone can account for a double-digit percentage of the mass. So a certificate should report net peptide content, determined by amino acid analysis or by nitrogen, alongside water by Karl Fischer or thermogravimetry, and counterion by ion chromatography or fluorine NMR.
Worked through: if net peptide content is 82 percent, a 10 mg gross vial holds about 10 mg × 0.82 = 8.2 mg of peptide. That is close to a fifth less peptide than the label weight implies. The cost-per-mg comparison is only meaningful once both quotes are on a net-peptide basis.
How is a FOXO4-DRI identity test run, step by step?
The evidence chain runs in a fixed order. A gap at any step should be written into your record as unconfirmed.
- Match the lot identifier on the COA, the chromatogram, the mass spectrum and the vial.
- Check the ESI-MS charge envelope. Isotope spacing within a peak should equal 1/z, and the 4+ and 5+ states should deconvolute to the same neutral mass.
- Compare the observed mass with the theoretical mass calculated from the printed sequence. The instrument and tolerance should be stated, and the value marked monoisotopic or average.
- Tie the target mass to the main peak with an LC-MS run, so the purity figure and the identity claim refer to the same substance.
- Look for a second chromatographic method with different selectivity, which tests for co-elution under the main peak.
- Confirm configuration separately, by chiral amino acid analysis, circular dichroism against an L reference, or a protease challenge.
If step six is missing, configuration was taken on the manufacturer's word.
What should the certificate show?
| Element | What to look for | If missing |
|---|---|---|
| Lot identifier | Same number on the COA, the chromatogram, the mass spectrum and the vial | Documents may describe different material; treat as unverified |
| Sequence statement | Explicit D-configuration and retro-inverso notation, not bare single-letter code | The defining feature of the compound is undocumented |
| Theoretical mass | Stated as monoisotopic or average, calculated from the printed sequence | No basis for judging the observed value |
| Observed mass | Instrument, tolerance, charge states used for deconvolution | A number, not a measurement |
| Chromatogram | Labeled axes, full run, column, gradient, wavelength, injection amount | Purity figure cannot be audited |
| Peak assignment | An LC-MS run linking the main peak to the target mass | Identity and purity refer to assumed-identical peaks |
| Chirality evidence | Chiral AAA, CD against an L reference, or protease resistance | Configuration is unconfirmed; record it that way |
| Content and water | Net peptide content, counterion, residual moisture and solvent | Label weight overstates peptide mass by an unknown margin |
| Analysis date and signature | Date after the manufacturing date, named analyst or laboratory | Possibly a template |
The recurring failure mode in practice is the representative document: a clean spectrum and a tidy chromatogram that belong to some earlier lot and were reissued with a new number typed into the header. Matching lot identifiers across every page is the cheapest check available, and it fails often enough to be worth doing every time. Our own quality standard sets out which of these elements travel with a lot.
What is the regulatory position?
FOXO4-DRI is not an approved medicine in any jurisdiction and is not, as far as public registries show, the subject of an authorized clinical investigation. The published record is preclinical: cell and rodent work following the 2017 Cell report, plus subsequent laboratory studies by other groups.
There is no USP or Ph. Eur. monograph for this peptide, which has a direct analytical consequence. No compendial identity test exists, no acceptance criteria are prescribed, and the supplier's method is the only method. Judging that method against the general expectations in ICH Q6B and the USP validation chapters is the work that falls to the purchasing laboratory.
Status verified August 26, 2026.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
Bottom line
FOXO4-DRI identity rests on two measurements read together. An ESI-MS mass has to match the printed sequence within a stated tolerance, and an LC-MS run has to tie that mass to the main peak. Neither one sees the retro-inverso design. Chirality needs chiral amino acid analysis, circular dichroism or a protease challenge, and if none appears, record configuration as taken on the manufacturer's word.
Common questions
How is FOXO4-DRI identity tested?
Can mass spectrometry confirm that the material is the D-retro-inverso form?
What mass tolerance should a certificate quote?
Why can a tryptic digest not be used for sequence confirmation?
Does 99 percent purity mean the vial is 99 percent peptide by weight?
Which single omission is worth rejecting a lot over?
Is a second chromatographic method necessary?
More documentation guides
Sources
- Baar et al., Cell, 2017. Primary report describing the FOXO4 D-retro-inverso construct, its TAT-derived import segment and its all-D backbone; supports the structural description and the preclinical-only status of the compound.
- USP General Chapter <1055>, Biotechnology-Derived Articles — Peptide Mapping. Establishes the compendial framework for sequence-level identity by enzymatic mapping, and by extension why that framework does not apply to a protease-resistant all-D peptide.
- ICH Q6B, Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. Supports the expectation that identity rests on orthogonal methods with stated acceptance criteria rather than a single chromatographic purity figure.
- Marfey, Carlsberg Research Communications, 1984. Introduces the chiral derivatizing reagent used to determine D and L amino acid ratios in hydrolysates; supports the chiral amino acid analysis method described here.
